ContributorsPublishersAdvertisers

FDA Approves Nab-Sirolimus for Advanced Malignant PEComa

targetedonc.com
 2021-11-23

Cover picture for the articleFDA approval has been granted to nab-sirolimus for intravenous use as treatment of patients with advanced malignant perivascular epithelioid cell tumors. The FDA has approved nab-sirolimus (Fyarro), a nanoparticle albumin-bound mTOR inhibitor, sirolimus albumin-bound nanoparticles for intravenous use as treatment of patients with advanced malignant perivascular epithelioid cell tumors (PEComa), according...

www.targetedonc.com

Comments / 0

Comments / 0